Format

Send to

Choose Destination
J Clin Invest. 2004 Jul;114(2):147-52.

Molecular mediators of hepatic steatosis and liver injury.

Author information

1
Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, 75390-9046, USA.

Abstract

Obesity and its associated comorbidities are among the most prevalent and challenging conditions confronting the medical profession in the 21st century. A major metabolic consequence of obesity is insulin resistance, which is strongly associated with the deposition of triglycerides in the liver. Hepatic steatosis can either be a benign, noninflammatory condition that appears to have no adverse sequelae or can be associated with steatohepatitis: a condition that can result in end-stage liver disease, accounting for up to 14% of liver transplants in the US. Here we highlight recent advances in our understanding of the molecular events contributing to hepatic steatosis and nonalcoholic steatohepatitis.

PMID:
15254578
PMCID:
PMC449757
DOI:
10.1172/JCI22422
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for American Society for Clinical Investigation Icon for PubMed Central
Loading ...
Support Center